µå·¯±×ÀÎÆ÷ ¾àǰ¿ä¾àÁ¤º¸ - ´ëÇÑÇÁ·ÎÄ«ÀÎ2%ÁÖ(ÇÁ·ÎÄ«Àο°»ê¿°) 20mL
µå·°ÀÎÆ÷¸¦ ½ÃÀÛÆäÀÌÁö·Î   ·Î±×ÀΠȸ¿ø°¡ÀÔ ³»ÄÁÅÙÃ÷ÇÔ contacts
BIT Druginfo
  ½ÅÅëÇÕ°Ë»ö  
¾àǰ°Ë»ö|ÀÓºÎÅõ¿©|ATCºÐ·ùÄÚµå|ÀûÀÀÁõ|ÇѾà(»ý¾à)»çÁø|¾àÈ¿ºÐ·ù
¾àǰ°Ë»ö Á¦Ç°½Äº° »óÈ£ÀÛ¿ë ¼ººÐÁ¤º¸ ȯÀÚº¹¾àÁöµµ ¾àÁ¦ºñ½É»çÁöħ ÇàÀ§°ü·Ã½É»çÁöħ °Ô½ÃÆÇ Ä¿¹Â´ÏƼ
 
 
top
¾ÆÀ̵ðÀúÀå
line
ȸ¿ø°¡ÀÔ ¾ÆÀ̵ðºñ¹Ð¹øÈ£Ã£±â
·Î±ä¹®Á¦
bottom
¾àǰ°Ë»ö
´ëÇÑÇÁ·ÎÄ«ÀÎ2%ÁÖ
Çٽɿä¾àÁ¤º¸
¿ä¾àÁ¤º¸
»ó¼¼Á¤º¸
´ëü°¡´É/µ¿ÀϼººÐÀǾàǰ
»óÈ£ÀÛ¿ë
°ü·Ã¾àÈ¿ºÐ·ù
±¹¼Ò¸¶ÃëÁ¦ (Local Anesthetics)
°ü·Ã¾à¹°Ã£±â
ȯÀÚº¹¾àÁöµµ
¿ä¾à º¹¾à ¾È³»¹®
»ó¼¼ º¹¾à ¾È³»¹®
Á¦Çüº° º¹¾àÁöµµ
Á¦Ç°º° º¹¾àÁöµµ
Áúȯº° º¹¾àÁöµµ
Á¾ÇÕ º¹¾à ¾È³»¹®
¾àÁ¦ºñ½É»çÁöħ
Disclaimer
¾Ë·ÁÁø Á¦Ç°º° ¾àÁ¦ºñ
½É»çÁöħÀÌ È®ÀεÇÁö ¾Ê¾Ò½À´Ï´Ù.
ÀϹݿøÄ¢ Á¶È¸¸¦ À§ÇØ Å¬¸¯Çϼ¼¿ä.
½É»ç»ç·Ê
±âŸ °Ë»ö
ATC Äڵ庰
¼ººÐº°
ÀûÀÀÁõº°
º´¿ë±Ý±â ÀǾàǰ
ÀӺαݱâ ÀǾàǰ
ºñ¿ëÈ¿°úÀû ÇÔ·® ÀǾàǰ
ATCÄÚµå °Ë»ö
ÀûÀÀÁõ °Ë»ö
»ý¾à¸í °Ë»ö
Medline °Ë»ö
Procaine HCl
My Drug Picture
My Drug List
¿ÀŸ½Å°í
bottom
Á¦Ç°ÄÚµå(KD)
Ç¥ÁØÄÚµå(¹ÙÄÚµå)
ǰ¸ñ±âÁØÄÚµå
bottom

ÇàÀ§Á¤ÀÇ+½É»çÁöħ
ÇàÀ§ Á¤ÀÇ
ÇàÀ§ ½É»çÁöħ
ÇàÀ§Á¤ÀÇ+½É»çÁöħ
ºÎ°¡Á¤º¸°Ë»ö
󹿻ç·Ê
ÀÌ»ó¹ÝÀÀ ¹× ´ëó¹ý
ÀÓ»êºÎ¸¦ À§ÇÑ
¿µ¾ç°ü¸®
ÀǾàǰ
¾ÈÀü»ç¿ë ¸Þ´º¾ó
KMLE ÀÇÇпë¾î
½º¸¶Æ®Æù
µå·°ÀÎÆ÷ ¸ð¹ÙÀÏ
bottom
 
 
 
   
¾àǰ°Ë»ö ¿ä¾àÁ¤º¸
 
 
´ëÇÑÇÁ·ÎÄ«ÀÎ2%ÁÖ(ÇÁ·ÎÄ«Àο°»ê¿°) 20mL  Procaine inj. 2% Daihan  
Àü¹®ÀǾàǰ | »èÁ¦ | ´ëü°¡´É/µ¿ÀϼººÐÀǾàǰ/´ëÁ¶¾à
 
¾Ë¸²: µå·°ÀÎÆ÷¿¡¼­´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù.
īī¿À½ºÅ丮 Æ®À§ÅÍ ÆäÀ̽ººÏ Á¤º¸°¡ºÎÁ·ÇϽŰ¡¿ä?
Àü¹®/ÀÏ¹Ý Àü¹®
¾àǰ»çÁø
¹«»öÅõ¸íÇÑ ¾×ÀÌ µé¾î ÀÖ´Â ¹«»öÅõ¸íÇÑ ¹ÙÀ̾ËÀÌ´Ù.
»çÁø»ó¼¼º¸±â  µ¿ÀϾà½Äº°»çÁø
ȸ¿øÁ¦°ø»çÁø
Á¦Á¶È¸»ç ´ëÇѾàǰ°ø¾÷(ÁÖ)
ÆÇ¸Åȸ»ç ´ëÇѾàǰ°ø¾÷(ÁÖ)
Çã°¡Á¤º¸ ÃëÇÏ (2025.10.01)
BIT ¾àÈ¿ºÐ·ù ±¹¼Ò¸¶ÃëÁ¦ (Local Anesthetics)
º¹ÁöºÎºÐ·ù 121[±¹¼Ò¸¶ÃëÁ¦ ]
û±¸ÄÚµå(KDÄÚµå)
   ºñ±Þ¿©Á¡°ËÄÚµå
645101031  
\0 ¿ø/20mL/º´(2024.11.01)(ÇöÀç¾à°¡)
\300 ¿ø/20mL/º´(2017.02.01) (º¯°æÀü¾à°¡)
ATCÄÚµå procaine / N01BA02
NDCÄÚµå [Proprietary Name Search _ ƯÇãµî·Ï¸í,»óÇ¥¸íÀ¸·Î °Ë»ö]
[Active Ingredient Search _ ÁÖ¼ººÐÀ¸·Î °Ë»ö]
[NDC Number Search _ NDCÄÚµå·Î °Ë»ö]
¼ººÐ / ÇÔ·® [½ÉÆò¿ø ÁÖ¼ººÐÄÚµå ±âÁØ ¼ººÐÇÔ·®Á¤º¸ Á¶È¸]

Procaine HCl 20mg  Á¦Ç° °Ë»ö
÷°¡Á¦ ÁÖ»ç¿ë¼ö
 
  ¸¶À̵巯±×ÀúÀå ¸¶À̵巯±×µµ¿ò¸»

Çã°¡Á¤º¸ Á¤º¸¿ä¾à ÄÚµå ¹× ºÐ·ùÁ¤º¸ Á¦Ç°Á¤º¸ º¹¾àÁ¤º¸ ½É»çÁ¤º¸ ÇмúÁ¤º¸ »ç¿ëÀÚÄÁÅÙÃ÷ Àüü
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù. À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î ·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
iconÇã°¡Á¤º¸
Ç׸ñ ³»¿ë
û±¸ÄÚµå(KDÄÚµå)
ºñ±Þ¿©Á¡°ËÄÚµå
»óÇѱݾ×
645101031   [º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/20mL/º´(2024.11.01)(ÇöÀç¾à°¡)
\300 ¿ø/20mL/º´(2017.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
ºü¸¥Á¶È¸
¿ä¾àÁ¤º¸ [È¿´É] [¿ë¹ý] [±Ý±â] [½ÅÁßÅõ¿©] [ÀÌ»ó¹ÝÀÀ]
»ó¼¼Á¤º¸ [È¿´É] [¿ë¹ý] [°æ°í] [±Ý±â] [½ÅÁßÅõ¿©] [ÀÌ»ó¹ÝÀÀ] [ÀϹÝÁÖÀÇ] [»óÈ£ÀÛ¿ë] [ÀÓ»êºÎ] [¼öÀ¯ºÎ] [¼Ò¾Æ] [°í·ÉÀÚ] [½ÅÀå¾ÖȯÀÚ] [°£Àå¾ÖȯÀÚ] [Àû¿ëÁÖÀÇ] [°ú·®Åõ¿©] [ÀÓ»ó°Ë»çÄ¡] [º¸°ü] [±âŸ]
Á¦Ç°¼º»ó ¹«»öÅõ¸íÇÑ ¾×ÀÌ µé¾î ÀÖ´Â ¹«»öÅõ¸íÇÑ ¹ÙÀ̾ËÀÌ´Ù.  [Á¦ÇüÁ¤º¸ È®ÀÎ]
Æ÷À塤À¯Åë´ÜÀ§ 10¹ÙÀ̾Ë/»óÀÚ(20mL/¹ÙÀ̾Ë)
ÁÖ¼ººÐÄÚµå 218230BIJ   [µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
Çã°¡»çÇ× ¿ø¹®Á¶È¸ [Çã°¡»çÇ× ¿ø¹®Á¶È¸]
È¿´ÉÈ¿°ú [ÀûÀÀÁõ º° °Ë»ö]   
°æ¸·¿Ü¸¶Ãë, Àü´Þ¸¶Ãë
¿ë¹ý¿ë·® * Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
   
[󹿾à¾î]
¡Û ¼ºÀÎ
1. °æ¸·¿Ü¸¶Ãë(±âÁØ ÃÖ°í¿ë·® 1ȸ 600§·) : ÇÁ·ÎÄ«Àο°»ê¿°À¸·Î¼­ º¸Åë ¼ºÀÎ 300-400§·À» Åõ¿©ÇÑ´Ù.
2. Àü´Þ¸¶Ãë : ÇÁ·ÎÄ«Àο°»ê¿°À¸·Î¼­ º¸Åë ¼ºÀÎ 10-400§·À» Åõ¿©ÇÑ´Ù.
Çʿ信 µû¶ó ¿¡Çdz×ÇÁ¸°(º¸Åë ³óµµ 1 : 10-20¸¸)À» ÷°¡ÇÏ¿© »ç¿ëÇÑ´Ù.
¿¬·É, ¸¶Ã뿵¿ª, ºÎÀ§, Á¶Á÷, Áõ»ó, üÁú, Àü½Å»óÅ¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
[BMIÁö¼ö °è»ê] [Body Surface Area °è»ê] [Cockcroft-Gault GFR °è»ê] [MDRD GFR °è»ê]
[ÇÇÇØ¾ß ÇÒ À½½Ä]
±Ý±â 1) (°æ¸·¿Ü¸¶Ãë) ÁßÁõÀÇ ÃâÇ÷ ¶Ç´Â ¼ï »óÅÂÀÇ È¯ÀÚ
2) (°æ¸·¿Ü¸¶Ãë) ÁÖ»çºÎÀ§ ¶Ç´Â ±× ÁÖÀ§¿¡ ¿°Áõ ȯÀÚ
3) (°æ¸·¿Ü¸¶Ãë) ÆÐÇ÷Áõ ȯÀÚ
4) ¸ÞÆ®Çì¸ð±Û·ÎºóÇ÷Áõ ȯÀÚ
5) ÀÌ ¾à ¶Ç´Â ±âŸÀÇ ¾È½ÄÇâ»ê¿¡½ºÅ׸£(ÄÚÄ«ÀÎ Á¦¿Ü)°è ±¹¼Ò¸¶ÃëÁ¦¿¡ °ú¹ÎÁõ ȯÀÚ

½ÅÁßÅõ¿© (°æ¸·¿Ü¸¶Ãë) ´ÙÀ½ ȯÀÚ¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÒ °Í.

1) ÁßÃ߽Űæ°è Áúȯ(¼ö¸·¿°, ȸ¹éô¼ö¿° µî) ȯÀÚ
2) ÀÓ»êºÎ
3) °í·ÉÀÚ
4) Ç÷¾× Áúȯ ¶Ç´Â Ç×ÀÀ°íÁ¦ Åõ¿© ȯÀÚ
5) ÁßÁõÀÇ °íÇ÷¾Ð ȯÀÚ
6) ôÁÖ¿¡ ÇöÀúÇÑ º¯Çü ȯÀÚ

ÀÌ»ó¹ÝÀÀ 1) ¼ï : ¼ïÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇϰí Ç÷¾ÐÀúÇÏ, ¾È¸éâ¹é, ¸Æ¹Ú ÀÌ»ó, È£Èí¾ïÁ¦ µîÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Áï½Ã Åõ¿©ÁßÁöÇϰí ÀΰøÈ£Èí, »ê¼ÒÈíÀÔ, ¼ö¾×, ź»ê³ªÆ®·ý, Ç÷¾Ð»ó½ÂÁ¦ Åõ¿©, ÀûÀýÇÑ Ã¼À§ À¯Áö µî ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
2) ÁßÃ߽Űæ°è
¨ç ÁøÀü, °æ·Ã µîÀÇ Áßµ¶ÇÑ Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇϰí ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Áï½Ã Åõ¿©ÁßÁöÇÏ°í µð¾ÆÁ¦ÆÊ ¶Ç´Â Ãʴܽð£Çü ¹Ù¸£ºñÅ»»ê Á¦Á¦(Ä¡¿ÀÆæÅ»³ªÆ®·ý) Åõ¿© µî ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
¨è Á¹À½, ºÒ¾È, ÈïºÐ, ¹«½Ã, ¾îÁö·¯¿ò, ±¸¿ª․±¸Åä, µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇÏ¿© ¼ï ¶Ç´Â Áßµ¶ÇÑ Áõ»óÀ¸·Î ÀÌÇàÇÏ´Â °Í¿¡ ÁÖÀÇÇϰí Çʿ信 µû¶ó ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
3) Ç÷¾× : µå¹°°Ô ¸ÞÆ®Çì¸ð±Û·ÎºóÇ÷ÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
4) °ú¹ÎÁõ : µÎµå·¯±â µîÀÇ ÇǺÎÁõ»ó, ºÎÁ¾ µîÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©ÁßÁöÇÑ´Ù.
[ÁÖ¿ä ÀÌ»ó¹ÝÀÀÁ¤º¸]
»óÈ£ÀÛ¿ë 1) ´ÙÀ½ ȯÀÚ¿¡ Åõ¿©ÇÏ´Â °æ¿ì¿¡´Â Ç÷°ü¼öÃàÁ¦(¿¡Çdz×ÇÁ¸°, ³ë¸£¿¡Çdz×ÇÁ¸°)À» ÷°¡ÇÏÁö ¾Ê´Â´Ù.
¨ç Ç÷°ü¼öÃàÁ¦¿¡ °ú¹ÎÁõ ȯÀÚ
¨è °íÇ÷¾Ð, µ¿¸Æ°æÈ­, ½ÉºÎÀü, °©»ó¼±±â´ÉÇ×Áø, ´ç´¢º´, Ç÷°ü°æ·Ã µîÀÌ Àִ ȯÀÚ
¨é (ħÀ±․Àü´Þ¸¶Ãë) ±Í, ¼Õ°¡¶ô․¹ß°¡¶ô ¶Ç´Â À½°æÀÇ ¸¶Ãë
2) ´ÙÀ½ ȯÀÚ¿¡ Ç÷°ü¼öÃàÁ¦(¿¡Çdz×ÇÁ¸°, ³ë¸£¿¡Çdz×ÇÁ¸°)¸¦ ÷°¡ÇÏ¿© Åõ¿©ÇÏ´Â °æ¿ì¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
¨ç ÇÒ·Îź µîÀÇ ÇÒ·Î°Õ ÇÔÀ¯ ÈíÀÔ¸¶ÃëÁ¦ Åõ¿© ȯÀÚ
¨è »ïȯ°è Ç׿ì¿ï¾à ¶Ç´Â MAOÀúÇØÁ¦ Åõ¿©ÁßÀΠȯÀÚ
Related FDA Approved Drug
±âÁØ ¼ººÐ:PROCAINE HYDROCHLORIDE
ACHROMYCIN (PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE)
CHLOROPROCAINE HYDROCHLORIDE (CHLOROPROCAINE HYDROCHLORIDE)
NESACAINE (CHLOROPROCAINE HYDROCHLORIDE)
NESACAINE-MPF (CHLOROPROCAINE HYDROCHLORIDE)
NOVOCAIN (PROCAINE HYDROCHLORIDE)
PROCAINE HYDROCHLORIDE (PROCAINE HYDROCHLORIDE)
PROCAINE HYDROCHLORIDE W/ EPINEPHRINE (EPINEPHRINE; PROCAINE HYDROCHLORIDE)
RAVOCAINE AND NOVOCAIN W/ LEVOPHED (NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE)
RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN (LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE)
TETRACYN (PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE)
  • ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-10-13
  • º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
¾Ë¸²
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼­ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.

°æ°í
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù. Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.

ÀüÈ­: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
About us |  Contact us |  FAQ |  Service ¾È³» |  ±¤°í ¹× Á¦È޾ȳ» |  °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ |  Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö |  SiteMap |  °í°´Áö¿ø